Keratinocyte growth factor in acute respiratory distress syndrome
- PMID: 28526232
- DOI: 10.1016/S2213-2600(17)30172-8
Keratinocyte growth factor in acute respiratory distress syndrome
Comment on
-
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.Lancet Respir Med. 2017 Jun;5(6):484-491. doi: 10.1016/S2213-2600(17)30171-6. Epub 2017 May 16. Lancet Respir Med. 2017. PMID: 28526233 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources